Cell line name |
MDA-MB-468rPCL20 |
Synonyms |
MDA-MB-468 rPaclitaxel20 |
Accession |
CVCL_D6VT |
Resource Identification Initiative |
To cite this cell line use: MDA-MB-468rPCL20 (RRID:CVCL_D6VT) |
Comments |
Group: Triple negative breast cancer (TNBC) cell line. Population: African American. Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Mutation; HGNC; HGNC:9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
- Mutation; HGNC; HGNC:9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast adenocarcinoma (NCIt: C5214) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0419 (MDA-MB-468) |
Sex of cell |
Female |
Age at sampling |
51Y |
Category |
Cancer cell line |
Publications | PubMed=40300663; DOI=10.1016/j.canlet.2025.217754 Helen E. Grimsley, Magdalena Antczak, Ian G. Reddin, Nicole Weiler, Katie-May McLaughlin, Florian Rothweiler, Johannes Haas, Andrea Nist, Marco Mernberger, Thorsten Stiewe, Tim R. Fenton ...Show all 19 authors... , Daniel Speidel, Catherine Harper-Wynne, Karina Cox, Dirk Heckl, Jindrich Cinatl Jr., Mark N. Wass, Michelle D. Garrett, Martin Michaelis; Show fewer authors Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers. Cancer Lett. 624:217754.1-217754.14(2025) |
Entry history |
Entry creation | 10-Sep-2024 |
Last entry update | 14-Aug-2025 |
Version number | 3 |
---|